Nucleic acid sequences can be delivered into specific cells via a diverse range of gene-based therapies and vaccines, including gene silencing/modulation (oligonucleotide-based drugs), gene therapy, gene modified cell therapy, DNA/RNA vaccines, and gene editing.
These large, complex modalities require compliant-ready analytical techniques for characterization and chemistry, manufacturing, and control (CMC) monitoring, but manual, error-prone, and laborious workflows often prevent routine analysis.
Waters brings industry-leading expertise, providing the analytical tools needed to support the development and commercialization of these exciting new modalities. With Waters, you can: